CN100380125C - 利用大环辅助配体检测prp的方法 - Google Patents
利用大环辅助配体检测prp的方法 Download PDFInfo
- Publication number
- CN100380125C CN100380125C CNB2003801067742A CN200380106774A CN100380125C CN 100380125 C CN100380125 C CN 100380125C CN B2003801067742 A CNB2003801067742 A CN B2003801067742A CN 200380106774 A CN200380106774 A CN 200380106774A CN 100380125 C CN100380125 C CN 100380125C
- Authority
- CN
- China
- Prior art keywords
- group
- prp
- assistant ligand
- big ring
- positive integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 46
- 230000008569 process Effects 0.000 title description 2
- 239000002671 adjuvant Substances 0.000 title 1
- 239000012472 biological sample Substances 0.000 claims abstract description 8
- 239000000725 suspension Substances 0.000 claims abstract description 7
- 239000000523 sample Substances 0.000 claims description 61
- 238000001514 detection method Methods 0.000 claims description 32
- 108010067770 Endopeptidase K Proteins 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
- VTJUKNSKBAOEHE-UHFFFAOYSA-N calixarene Chemical class COC(=O)COC1=C(CC=2C(=C(CC=3C(=C(C4)C=C(C=3)C(C)(C)C)OCC(=O)OC)C=C(C=2)C(C)(C)C)OCC(=O)OC)C=C(C(C)(C)C)C=C1CC1=C(OCC(=O)OC)C4=CC(C(C)(C)C)=C1 VTJUKNSKBAOEHE-UHFFFAOYSA-N 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 150000001412 amines Chemical class 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 14
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- 125000000524 functional group Chemical group 0.000 claims description 11
- 150000002430 hydrocarbons Chemical group 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000002015 acyclic group Chemical group 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 5
- 238000007306 functionalization reaction Methods 0.000 claims description 5
- 150000001261 hydroxy acids Chemical group 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 5
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 239000013060 biological fluid Substances 0.000 claims description 4
- 230000007170 pathology Effects 0.000 claims description 4
- 241000282849 Ruminantia Species 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 102000057593 human F8 Human genes 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 229940047431 recombinate Drugs 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 2
- 206010044565 Tremor Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 108091000054 Prion Proteins 0.000 abstract description 16
- 102000029797 Prion Human genes 0.000 abstract description 5
- 230000001717 pathogenic effect Effects 0.000 abstract description 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 51
- 239000011049 pearl Substances 0.000 description 40
- 238000011534 incubation Methods 0.000 description 34
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 25
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 17
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 17
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 17
- 230000003287 optical effect Effects 0.000 description 15
- 238000005406 washing Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 102100034452 Alternative prion protein Human genes 0.000 description 12
- 230000003213 activating effect Effects 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 102000003992 Peroxidases Human genes 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 108040007629 peroxidase activity proteins Proteins 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000008521 reorganization Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010013786 Dry skin Diseases 0.000 description 7
- 238000013016 damping Methods 0.000 description 7
- 230000008021 deposition Effects 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000006277 sulfonation reaction Methods 0.000 description 6
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000010445 mica Substances 0.000 description 5
- 229910052618 mica group Inorganic materials 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 101000573901 Homo sapiens Major prion protein Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000011888 autopsy Methods 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011010 flushing procedure Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 239000011976 maleic acid Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 208000024777 Prion disease Diseases 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000000389 anti-prion effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000007669 thermal treatment Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- 101100001471 Schizosaccharomyces pombe (strain 972 / ATCC 24843) alm1 gene Proteins 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 101150118925 bioM gene Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- UIMOJFJSJSIGLV-JNHMLNOCSA-N carumonam Chemical compound O=C1N(S(O)(=O)=O)[C@H](COC(=O)N)[C@@H]1NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1 UIMOJFJSJSIGLV-JNHMLNOCSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000003382 ingestive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001314 profilometry Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 238000004621 scanning probe microscopy Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000005211 surface analysis Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/823—Immunogenic carrier or carrier per se
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/807—Hapten conjugated with peptide or protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Transmission And Conversion Of Sensor Element Output (AREA)
Abstract
Description
仅有AML | AML/recPrP1/1000 | AML/recPrP1/100 | AML/recPrP1/10 | 仅有recPrP | |
Ra(nm) | 48 | 69,6 | 123,9 | 134,4 | 1,11 |
RMS(nm) | 58,7 | 82,8 | 149 | 163,1 | 1,95 |
平均高度 | 217,7 | 233,3 | 408,7 | 469,8 | 5,4 |
最大高度值 | 448,9 | 484,3 | 894,66 | 1056,9 | 43,17 |
Claims (29)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0216383A FR2849205B1 (fr) | 2002-12-20 | 2002-12-20 | Procede d'amplification de la detection de la prpsc et utilisation d'un ligand adjuvant macrocyclique pour une telle amplification |
FR02/16383 | 2002-12-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1729397A CN1729397A (zh) | 2006-02-01 |
CN100380125C true CN100380125C (zh) | 2008-04-09 |
Family
ID=32406305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003801067742A Expired - Fee Related CN100380125C (zh) | 2002-12-20 | 2003-12-19 | 利用大环辅助配体检测prp的方法 |
Country Status (14)
Country | Link |
---|---|
US (2) | US7217530B2 (zh) |
EP (1) | EP1573337B1 (zh) |
JP (1) | JP2006510914A (zh) |
CN (1) | CN100380125C (zh) |
AT (1) | ATE354095T1 (zh) |
AU (1) | AU2003299390B2 (zh) |
BR (1) | BR0317080A (zh) |
DE (1) | DE60311871T2 (zh) |
DK (1) | DK1573337T3 (zh) |
ES (1) | ES2282733T3 (zh) |
FR (1) | FR2849205B1 (zh) |
MX (1) | MXPA05006766A (zh) |
PT (1) | PT1573337E (zh) |
WO (1) | WO2004059322A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2849205B1 (fr) * | 2002-12-20 | 2005-02-11 | Afssa | Procede d'amplification de la detection de la prpsc et utilisation d'un ligand adjuvant macrocyclique pour une telle amplification |
DE10328125A1 (de) * | 2003-06-23 | 2005-01-13 | Roche Diagnostics Gmbh | Nachweis von Protease-resistentem Prion-Protein nach spontaner Transformationsreaktion |
FR2865280B1 (fr) * | 2004-01-20 | 2007-01-12 | Biomerieux Sa | Procede de detection de la prp utilisant une molecule ayant au moins une charge positive et/ou au moins une liaison osidique et un ligand autre qu'un ligand proteique |
FR2865279A1 (fr) * | 2004-01-20 | 2005-07-22 | Biomerieux Sa | Procede de detection de la prp utilisant une molecule ayant au moins une charge positive et/ou au moins une liaison osidique et un ligand autre qu'un ligand proteique |
FR2888937B1 (fr) * | 2005-07-21 | 2012-10-26 | Biomerieux Sa | Procede de detection des fcpa utilisant un agent d'agregation des fcpa et un agent de capture des agregats formes |
WO2010001619A1 (ja) * | 2008-07-04 | 2010-01-07 | 積水メディカル株式会社 | 免疫学的測定における感度増強方法又はヘモグロビンの影響回避方法 |
WO2013091074A1 (en) * | 2011-12-21 | 2013-06-27 | Uvic Industry Partnerships Inc. | Method and array for identifying histone-code-related analytes |
US10338037B2 (en) | 2015-08-18 | 2019-07-02 | Uvic Industry Partnerships Inc. | Compounds and conjugates for identifying and separating post-translationally modified analytes |
US11629128B2 (en) | 2019-06-25 | 2023-04-18 | Uvic Industry Partnerships Inc. | Compound and dimer complex embodiments for supramolecular sensing |
CN113876760B (zh) * | 2021-10-26 | 2022-12-23 | 南开大学 | 杯芳烃和/或杯芳烃的衍生物在制备治疗创伤性脑损伤的药物中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571911A (en) * | 1992-06-19 | 1996-11-05 | The Trustees Of Columbia University In The City Of New York | Method of purifying organic compounds using an enantioselective receptor |
WO1997037995A1 (en) * | 1996-04-05 | 1997-10-16 | Board Of Regents, The University Of Texas System | Calixpyrroles, calixpyridinopyrroles and calixpyridines |
CN1342266A (zh) * | 1999-01-08 | 2002-03-27 | 美国政府农业部 | 提取朊病毒蛋白的方法和试剂盒 |
WO2002086511A2 (de) * | 2001-04-21 | 2002-10-31 | Prionics Ag | VERFAHREN ZUR UNTERSUCHUNG VON PRION-PROTEIN ENTHALTENDEN PROBEN AUF DAS EVENTUELLE VORLIEGEN DER PrPSc-FORM |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5312837A (en) * | 1991-01-29 | 1994-05-17 | Genelabs Technologies, Inc. | Method of treating viral infections with aryl macrocyclic compounds |
WO1997041856A1 (en) * | 1996-05-08 | 1997-11-13 | Massachusetts Institute Of Technology | ORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO) |
US5891641A (en) * | 1997-02-21 | 1999-04-06 | The Regents Of The University Of California | Assay for disease related conformation of a protein |
CA2385743A1 (en) * | 1999-09-28 | 2001-04-05 | Universitat Zurich | Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis |
AU2001251358A1 (en) * | 2000-04-05 | 2001-10-23 | V.I. Technologies, Inc. | Prion-binding ligands and methods of using same |
DE10107083C2 (de) * | 2001-02-13 | 2003-02-20 | Abdulgabar Salama | Pentosan Polysulfat als Ligand zum Nachweis von Prionen |
FR2849205B1 (fr) * | 2002-12-20 | 2005-02-11 | Afssa | Procede d'amplification de la detection de la prpsc et utilisation d'un ligand adjuvant macrocyclique pour une telle amplification |
-
2002
- 2002-12-20 FR FR0216383A patent/FR2849205B1/fr not_active Expired - Fee Related
-
2003
- 2003-12-19 AU AU2003299390A patent/AU2003299390B2/en not_active Ceased
- 2003-12-19 MX MXPA05006766A patent/MXPA05006766A/es active IP Right Grant
- 2003-12-19 EP EP03799682A patent/EP1573337B1/fr not_active Expired - Lifetime
- 2003-12-19 WO PCT/FR2003/003857 patent/WO2004059322A1/fr active IP Right Grant
- 2003-12-19 JP JP2004563299A patent/JP2006510914A/ja active Pending
- 2003-12-19 BR BR0317080-2A patent/BR0317080A/pt not_active IP Right Cessation
- 2003-12-19 ES ES03799682T patent/ES2282733T3/es not_active Expired - Lifetime
- 2003-12-19 DK DK03799682T patent/DK1573337T3/da active
- 2003-12-19 DE DE60311871T patent/DE60311871T2/de not_active Expired - Lifetime
- 2003-12-19 AT AT03799682T patent/ATE354095T1/de not_active IP Right Cessation
- 2003-12-19 PT PT03799682T patent/PT1573337E/pt unknown
- 2003-12-19 CN CNB2003801067742A patent/CN100380125C/zh not_active Expired - Fee Related
-
2005
- 2005-06-09 US US11/148,945 patent/US7217530B2/en not_active Expired - Fee Related
-
2007
- 2007-02-01 US US11/701,334 patent/US20070154885A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571911A (en) * | 1992-06-19 | 1996-11-05 | The Trustees Of Columbia University In The City Of New York | Method of purifying organic compounds using an enantioselective receptor |
WO1997037995A1 (en) * | 1996-04-05 | 1997-10-16 | Board Of Regents, The University Of Texas System | Calixpyrroles, calixpyridinopyrroles and calixpyridines |
CN1342266A (zh) * | 1999-01-08 | 2002-03-27 | 美国政府农业部 | 提取朊病毒蛋白的方法和试剂盒 |
WO2002086511A2 (de) * | 2001-04-21 | 2002-10-31 | Prionics Ag | VERFAHREN ZUR UNTERSUCHUNG VON PRION-PROTEIN ENTHALTENDEN PROBEN AUF DAS EVENTUELLE VORLIEGEN DER PrPSc-FORM |
Also Published As
Publication number | Publication date |
---|---|
DK1573337T3 (da) | 2007-06-11 |
DE60311871D1 (de) | 2007-03-29 |
JP2006510914A (ja) | 2006-03-30 |
PT1573337E (pt) | 2007-05-31 |
AU2003299390B2 (en) | 2007-11-01 |
AU2003299390A1 (en) | 2004-07-22 |
EP1573337B1 (fr) | 2007-02-14 |
US20060019311A1 (en) | 2006-01-26 |
ES2282733T3 (es) | 2007-10-16 |
FR2849205A1 (fr) | 2004-06-25 |
BR0317080A (pt) | 2005-10-25 |
FR2849205B1 (fr) | 2005-02-11 |
AU2003299390A8 (en) | 2004-07-22 |
ATE354095T1 (de) | 2007-03-15 |
DE60311871T2 (de) | 2007-10-31 |
MXPA05006766A (es) | 2006-02-17 |
WO2004059322A8 (fr) | 2005-07-14 |
CN1729397A (zh) | 2006-02-01 |
US20070154885A1 (en) | 2007-07-05 |
EP1573337A1 (fr) | 2005-09-14 |
US7217530B2 (en) | 2007-05-15 |
WO2004059322A1 (fr) | 2004-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7217530B2 (en) | Process for detecting PrP using a macrocyclic adjuvant ligand | |
Izui et al. | Features of systemic lupus erythematosus in mice injected with bacterial lipopolysaccharides: identificantion of circulating DNA and renal localization of DNA-anti-DNA complexes. | |
CN104937422B (zh) | 用于检测维生素d的组合物和方法 | |
Landry et al. | Systemic lupus erythematosus. Studies of the antibodies bound to skin | |
JPH11511558A (ja) | 蛍光および発光ラベル組成物ならびにそれらの使用方法 | |
MXPA05011159A (es) | Metodo para identificar ligandos especificos para isoformas estructurales de proteinas. | |
CN107589249A (zh) | 用于通过免疫复合物转移法检测被检物质的抗体试剂及其制造方法、以及该抗体试剂的用途 | |
JPS6120867A (ja) | 抗体‐レクチンのサンドイツチ検定 | |
CN101413955A (zh) | 一种检测玉米赤霉烯酮的elisa测试盒及制备及检测方法 | |
KR19990071477A (ko) | 염증성질환의진단방법및매개체 | |
CN110161247A (zh) | 检测抗环瓜氨酸肽抗体的均相免疫检测试剂盒及其应用 | |
Burrell et al. | Lung antibodies in patients with pulmonary disease | |
FR2486657A1 (fr) | Procede de detection et de dosage d'une substance biologique par erythroadsorption | |
CN106771150A (zh) | 一种检测烯酰吗啉残留的elisa检测试剂盒及检测方法 | |
CN106939034A (zh) | 用于鉴定受试者所感染的hev基因型的方法和试剂盒 | |
US4877726A (en) | Method for the detection of acute-phase toxoplasma infection | |
FR2709492A1 (fr) | Méthode d'immunodosage spécifique de la glutathion peroxydase plasmatique humaine, kit pour sa mise en Óoeuvre, oligopeptides et anticorps spécifiques de la méthode . | |
Collins et al. | Solid-phase Clq-binding fluorescence immunoassay for detection of circulating immune complexes | |
MXPA06008165A (es) | Metodo para detectar proteina patologica prp usando al menos una carga positiva y/o al menos un enlace glucosidico y un ligando diferente de un ligando de proteina. | |
FR2790093A1 (fr) | Procede d'analyse immunologique par reaction d'adherence | |
JP2018135302A (ja) | 特定のサルファイド化合物に結合する抗体及びその使用 | |
FR2788603A1 (fr) | PROCEDE D'IMMUNOANALYSE D'UNE PROTEINE MATRICIELLE OLIGOMERIQUE DU CARTILAGE -comp-, SONDE ANTIGENIQUE, ANTICORPS ET NECESSAIRE D'IMMUNOANALYSE UTILISE POUR LA MISE EN OEUVRE DE CE PROCEDE | |
CN1971277A (zh) | 一种异丙隆直接竞争酶联免疫吸附分析方法及其试剂盒 | |
Losso et al. | Fluorescence quenching of heat‐treated immunoglobulins and determination of their biological activity by PCFIA | |
SU1689858A1 (ru) | Способ определени антигена |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CI01 | Publication of corrected invention patent application |
Correction item: Applicant Correct: Claude Bernal Lyon University False: Claude Bernal Leon University Number: 05 Volume: 22 |
|
CI02 | Correction of invention patent application |
Correction item: Applicant Correct: Claude Bernal Lyon University False: Claude Bernal Leon University Number: 05 Page: The title page Volume: 22 |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080409 Termination date: 20100119 |